Vancomycin is designed to help reduce medication errors and features the company’s PreventIV Measures packaging and labeling.
The injection is used to treat infections caused by susceptible strains of methicillin-resistant (beta lactam-resistant) staphylococci for penicillin, cephalosporins allergic patients.
It is also used to treat the infections caused by vancomycin-susceptible organisms, which are resistant to other antimicrobial drugs.
The US market for Vancomycin Hydrochloride for injection, USP was nearly $186m out of which nearly 50% of the sales was pharmacy bulk packages for the 12 months ending June 2012, according to IMS.